Permanent pacemaker implantation remains the standard of care for symptomatic sick sinus syndrome (SSS) — for symptomatic bradycardia, sinus pauses, or chronotropic incompetence — and no pharmacologic or device alternative has displaced it. The most interesting recent progress is mechanistic: genome-wide studies have identified risk variants (in genes such as MYH6 and KRT8) and, through Mendelian randomization, supported atrial fibrillation and a lower heart rate as causal contributors to SSS, while metabolic factors appear non-causal. This is deepening understanding of why the sinus node fails and pointing toward possible upstream targets (atrial remodeling, neuromodulation), though these remain experimental.
Further reading: genetic insight into SSS (Thorolfsdottir et al., European Heart Journal 2021); sinus node dysfunction and atrial fibrillation review (Duan & Du, 2023).